Related Experiment Video
Updated: Jun 15, 2025
08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
7.3K
Nanomedicines for cardiovascular disease
Bryan Ronain Smith1, Elazer R Edelman2,3
1Department of Biomedical Engineering and Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI, USA. smit2901@msu.edu.
Nature Cardiovascular Research
|August 28, 2024
Summary
Nanomedicine offers new hope for cardiovascular disease (CVD) treatment and diagnosis. Advances in nanomaterials are poised to significantly improve therapies, imaging, and diagnostics for heart and blood vessel conditions.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiovascular Medicine
Background:
- Cardiovascular disease (CVD) is the leading global cause of mortality.
- Current CVD therapeutic and diagnostic options have limitations.
- Nanomedicine presents transformative potential for CVD management.
Purpose of the Study:
- To review recent advances in nanomedicine for cardiovascular disease.
- To highlight key clinical opportunities in CVD nanomedicine.
- To discuss the application of nanomaterials in cardiac, vascular, and diagnostic contexts.
Main Methods:
- Review of current nanomedicine applications in CVD.
- Analysis of nanomaterial integration in cardiac biomaterials.
- Examination of nanotherapeutics and nanodiagnostics for vasculature.
- Assessment of nano-enabled ex vivo diagnostics.
Main Results:
- Nanomaterials enhance cardiac biomaterials (mechanical, immunological, electrical).
- Systemic nanotherapeutics and nanodiagnostics target vasculature.
- Nanotechnology improves ex vivo diagnostic sensitivity and specificity.
- Emerging CVD immunotherapy and immunoimaging show significant promise.
Conclusions:
- Nanomedicine is on the verge of substantially impacting CVD patient care.
- Clinical trials and preclinical strategies demonstrate nanomedicine's potential.
- Key clinical opportunities exist in the rapidly evolving field of CVD nanomedicine.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:16Antianginal Drugs: Nitrates and β-Blockers
547
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
547
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
68
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322